William Blair research analyst Matt Phipps was quoted in MedCity News following Bristol Myers Squibb’s acquisition of Mirati Therapeutics. Phipps weighed in on the target of the acquisition, cancer drug Krazati.

Equity Research
William Blair research analyst Matt Phipps was quoted in MedCity News following Bristol Myers Squibb’s acquisition of Mirati Therapeutics. Phipps weighed in on the target of the acquisition, cancer drug Krazati.
Stay up-to-date with the latest William Blair news and insights
Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures